Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Rodanthi Syrigou
Institutions:
National and Kapodistrian University of Athens,
Alexandra Hospital
Observed institutions:
National and Kapodistrian University of Athens,
Alexandra Hospital
ORCID:
0009-0000-9357-1694
Observed ORCID:
0009-0000-9357-1694
OpenAlex ID:
A5109652628
Remnant cholesterol and atherosclerotic disease in high cardiovascular risk patients. Beyond LDL cholesterol and hypolipidemic treatment
2022
·
Dimitrios Delialis
, Georgios Georgiopoulos
, et al.
·
Hellenic Journal of Cardiology
·
20
PDF
Management and Outcomes of Anti-CD38 Refractory Patients: The Impact of Retreatment and of Subsequent Therapies
2023
·
Efstathios Kastritis
, Foteini Theodorakakou
, et al.
·
HemaSphere
·
9
Real World Efficacy and Toxicity of Selinexor: Importance of Patient Characteristics, Dose Intensity and Post Progression Outcomes
2023
·
Efstathios Kastritis
, Maria Gavriatopoulou
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
9
Evaluation of a novel method to guide belantamab mafodotin dosing in multiple myeloma based on a patient-reported questionnaire.
2024
·
Evangelos Terpos
, Maria Gavriatopoulou
, et al.
·
Journal of Clinical Oncology
·
4
Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies
2023
·
Efstathios Kastritis
, Panagiotis Malandrakis
, et al.
·
Blood
·
4
PDF
Long-Term Safety and Efficacy Results of Belantamab Mafodotin Plus Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: An Updated Part 1 Analysis from the Phase 1/2 Belard Trial
2023
·
Evangelos Terpos
, Maria Gavriatopoulou
, et al.
·
Blood
·
4
Management and Outcomes of Anti-CD38 Refractory Myeloma Patients: The Impact of Retreatment and of Subsequent Therapies
2022
·
Efstathios Kastritis
, Foteini Theodorakakou
, et al.
·
Blood
·
4
Prevalence of Peripheral Neuropathy (PN) Among Patients with Asymptomatic Monoclonal Gammopathies: A Clinical & Electrophysiological Study
2023
·
Panagiotis Zis
, Rodanthi Syrigou
, et al.
·
Blood
·
2
P884: Belantamab Mafodotin Plus Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: Updated Results From the Phase 1/2 Belard Study
2023
·
Evangelos Terpos
, Maria Gavriatopoulou
, et al.
·
HemaSphere
·
2
Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: The phase 1/2, prospective, open-label, BelaRd study.
2023
·
Evangelos Terpos
, Maria Gavriatopoulou
, et al.
·
Journal of Clinical Oncology
·
2
A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
2022
·
Evangelos Terpos
, Maria Gavriatopoulou
, et al.
·
Blood
·
2
A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
2022
·
Evangelos Terpos
, Efstathios Kastritis
, et al.
·
Blood
·
2
Real World Efficacy and Toxicity of Selinexor: Importance of Dose Intensity and Post Progression Outcomes
2022
·
Efstathios Kastritis
, Panagiotis Malandrakis
, et al.
·
Blood
·
2
Less Is More: Deciphering the Association between Ocular Adverse Events and Clinical Activity of Belantamab Mafodotin in Multiple Myeloma
2024
·
Evangelos Terpos
, Maria Gavriatopoulou
, et al.
·
Blood
·
1
PDF
Evaluation of a Novel Method for the Assessment of Ocular Adverse Events and Associated Functional Impact in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in the Phase 1/2 Belard Trial
2023
·
Evangelos Terpos
, Ioannis Ntanasis-Stathopoulos
, et al.
·
Blood
·
1
PDF
Ocular adverse events in transplant ineligible patients with newly diagnosed multiple myeloma treated with belantamab mafodotin plus lenalidomide/dexamethasone from the phase 1/2 BelaRd study.
2023
·
Evangelos Terpos
, Ioannis Ntanasis-Stathopoulos
, et al.
·
Journal of Clinical Oncology
·
1
Extrahepatic endocrine manifestations of chronic HCV infection
2026
·
Katerina Stefanaki
, Efthymios-Leonidas Kaltsounis
, et al.
·
Annals of Hepatology
PDF
Indeterminate-Grey Zone of HBeAg-Negative Chronic Hepatitis B Is Associated with a Higher Risk of Hepatocellular Carcinoma Compared to HBeAg-Negative Chronic Infection—A Systematic Review and Meta-Analysis
2026
·
Rodanthi Syrigou
, Dimitra Tiganiti
, et al.
·
Livers
PDF
Circulating tumor cells (CTCs) combined with frailty index offer an improved stratification system for transplant-ineligible newly diagnosed multiple myeloma patients
2025
·
Ioannis Kostopoulos
, Ioannis Ntanasis-Stathopoulos
, et al.
·
Blood
P-283 How To Effectively Administer Belantamab Mafodotin: Knowledge Gained From the Phase 1/2 BelaRd Study in Newly Diagnosed Transplant-Ineligible Patients With Multiple Myeloma
2024
·
Evangelos Terpos
, Maria Gavriatopoulou
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
A Phase II Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Patients with Multiple Myeloma Progressing on or after One Line of Lenalidomide-Containing Therapy
2023
·
Evangelos Terpos
, Maria Gavriatopoulou
, et al.
·
Blood
Curability of Light Chain (AL) Amyloidosis with Conventional Dose Regimens
2023
·
Foteini Theodorakakou
, Despina Fotiou
, et al.
·
Blood
An Updated Analysis of Ocular Adverse Events and Vision-Related Functioning in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in the Phase 1/2 Belard Trial
2023
·
Evangelos Terpos
, Ioannis Ntanasis-Stathopoulos
, et al.
·
Blood
PDF
Incidence of Second Primary Malignancies in Patients with AL Amyloidosis and the Impact of Disease Stage and Therapies
2023
·
Efstathios Kastritis
, Vasiliki Spiliopoulou
, et al.
·
Blood
A Phase 2 Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment
2023
·
Evangelos Terpos
, Efstathios Kastritis
, et al.
·
Blood
PDF
Show more works
View as search
Works count:
29
Citation count:
69
H-index:
4
I10-index:
1
Year
Topic
Type